Biomedical Advanced Research and Development Authority (BARDA)

Market Research

Name: Stabilization Technologies for CBRN Medical Countermeasures

Issue Date: January 26, 2026

Responses Due: February 19, 2026, 1 PM ET

Biomedical Advanced Research Development Authority (BARDA) Contracts Management & Acquisition (CMA)
400 7th Street, SW, Washington, DC 20024

MedicalCountermeasures.gov

Purpose:

The Biomedical Advanced Research and Development Authority (BARDA), Chemical, Biological, Radiological, and Nuclear (CBRN) Division is conducting targeted market research to inform a potential future initiative focused on stabilization technologies for biologic medical countermeasures (MCMs). Technologies applicable to protein-based vaccines, viral-vectored vaccines, and monoclonal antibodies (mAbs) or related biologics (e.g., single domain antibodies) are of primary interest, with preference for platforms that may be broadly applicable across multiple CBRN indications.

Scope of Interest:

The BARDA CBRN Division seeks input from industry regarding stabilization approaches that may:

- Extend the shelf life of CBRN MCMs
- Reduce or eliminate frozen or ultra-cold chain storage requirements
- Improve long-term stockpile sustainment and logistical flexibility

Approaches of interest may include, but are not limited to, formulation-based methods; physical state modifications (e.g., drying, lyophilization, or vitrification); encapsulation or matrix-based platforms; and novel excipient, stabilizer, or carrier systems.

Technologies should be applicable to one or more of the following bulk drug substance (BDS) and/or finished drug product categories. While applicability at the BDS stage is preferred, technologies that can be applied at the finished product stage are also of interest. Preference is sought for platform technologies that are broadly applicable across multiple CBRN biologic product types; however, technologies addressing a single agent or product are acceptable.

Applicable product categories include:

- Protein-based vaccines
- Viral-vectored vaccines
- Monoclonal antibodies or related biologics intended for prophylaxis or treatment

Submitters should clearly describe whether the stabilization process can be implemented in-house by a product sponsor or BARDA-supported facility, or whether shipment of BDS or finished material to the technology provider is required. Any specialized facilities, equipment, containment, or biosafety requirements associated with implementation should be identified.

Ideally, the technology can be applied to existing BDS with minimal or no reformulation and without significant changes to established upstream or downstream manufacturing processes.

Submission Requirements:
Any interested organization may submit a brief (one-page) capabilities statement that addresses the requirements and scope described in this notice.

Capabilities should address, at a minimum:

- Technical applicability
- Operational and implementation model
- Technology maturity and current development status

Submissions must be received no later than:

- **Date:** February 19, 2026
- **Time:** 1 PM ET

Capabilities statements should be submitted electronically in Microsoft Word or PDF format via the following link:
https://atisc.formstack.com/forms/stabilization_technologies_for_cbrn_medical_countermeasures_biomap

Submissions will be reviewed by the BARDA CBRN Division in advance of the upcoming BioMaP-Consortium General Membership Meeting to help inform discussion topics and potential follow-on engagement.